COVISHIELD News
According to AstraZeneca, the vaccination has been replaced by revised shots that address novel variations.
TTS is thrombosis with thrombocytopenia syndrome, which is a clot in blood vessels of the brain or elsewhere, along with a low platelet count
TTS has emerged as a rare but significant concern associated with the AstraZeneca Covid-19 vaccine
A doctor, however, emphasised that these findings don't change the fact that the vaccines were essential to fight COVID-19
A man has filed a petition seeking a response from the makers of Covishield claiming that the vaccine caused his daughter's death
He has demanded a compensation of Rs 1,000 crore from the Indian-vaccine maker Serum Institute of India (SII)
Govt clears Corbevax as Covid-19 booster dose for adults vaccinated with Covaxin, Covishield
Health Ministry's approval is based on the recommendations made by the NTG
Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 immunisation programme.
CORBEVAX has become the first vaccine in India to get DCGI approval for COVID-19 booster dose.
People who are 18 years & above & have already taken two doses of either COVISHIELD or COVAXIN can now receive a dose of CORBEVAX.
The vaccine can be taken after 6 months of two doses of Covaxin or Covishield vaccines for restricted use in emergency situation.
Monkeypox outbreak: Social media posts claiming the chimpanzee adenovirus vector used in AstraZeneca's Covid vaccine, causes Monkeypox have surfaces, PTI reported.
Sputnik booster dose has been approved in India.
Over 6.5 lakh people who have received Sputnik vaccine will be eligible to take the booster dose.
India had earlier approved a third dose of COVID vaccines – Covaxin and Covishield – for adults.
Several vials of Covid vaccine found in a garbage dump in UP.
A probe has been ordered in this regard.
A vial of Covishield is opened only when 10 patients are available to take the dose.
Government have decided to allow Coronavirus booster shots to all adults from Sunday
The third jab will not be free for most adults
Mr Poonawala said that Serum Institute will offer large discounts to hospitals and distributors
Speaking to reporters on the sidelines of the ‘Alternate Fuel Conclave’, the SII CEO said the reason behind the low number of Covid-19 cases at the moment is that the country chose the right vaccine.
India's apex body on immunisation NTAGI has recommended administering the second dose of Covishield between eight and 16 weeks after the first dose.
The National Technical Advisory Group on Immunisation has recommended reducing the Covishield dose gap.
Presently, the second dose of Covishield is being administered 12-16 weeks after the first dose.
India continues on a downward trend of new Covid cases.
Health ministry has denied Covishield doses going to waste reports.
The health ministry said states were advised that no vaccine dose gets expired.
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year
Serum Institue of India had submitted application to DCGI seeking regular market approval for Covishiled
An expert panel of India's central drug authority on Wednesday recommended granting regular market approval to Covid vaccines Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said.
A total of 330 volunteers, who were not vaccinated and had no history of the COVID-19 infection, were selected and screened for SARS-CoV-2 antibodies for the study.
Scientific data available says that vaccines provide antibodies, said Dr JA Jayala
It will be preventing you and helping you to come out of the severe infection, said Jayala
The SII has recently filed an application with the DCGI regarding approval for a booster dose of Covishield
It cited that there is adequate stock of the Covid vaccine in the country
A demand for a booster shot is there due to the emergence of new coronavirus variants
SII cited adequate stock of the vaccine in the country and a demand for a booster.
Loading...